Alnylam Q3 product rev $167M; Founder CEO to step down, Greenstreet to become CEO Jan 2022

ALNYLAM PHARMACEUTICALS, INC.

Q3 2021 net product revenues $167M (ONPATTRO $120M, GIVLAARI $32M, OXLUMO $15M); GAAP net loss $204.5M ($1.72 loss per share).
FY 2021 guidance reiterated: combined net product revenues $640M-$665M; GAAP R&D+SG&A $1.335B-$1.455B.
Founding CEO John Maraganore to step down Dec 31, 2021; President/COO Yvonne Greenstreet appointed CEO effective Jan 1, 2022.
Maraganore to consult through Mar 31, 2022 and remain on Scientific Advisory Board; Greenstreet also appointed to Board.
Cash and investments $2.33B as of Sep 30, 2021, up from $1.87B at Dec 31, 2020 due to Blackstone payment and credit facility draw.

item 2.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Yvonne L. Greenstreet

Director

ALNY · ALNYLAM PHARMACEUTICALS, INC.

Effective: 2021-10-28
Filed: October 28, 2021, 7:59 PM ET

the Board expanded the size of the Board from eleven to twelve members and elected Dr. Greenstreet to fill the newly created vacancy, in each case effective as of October 28, 2021.

Departed

John M. Maraganore

Chief Executive Officer

ALNY · ALNYLAM PHARMACEUTICALS, INC.

Effective: 2021-12-31
Successor: Yvonne L. Greenstreet
Filed: October 28, 2021, 7:59 PM ET

The Company also announced that, as part of this leadership transition, following nearly 19 years of service, John M. Maraganore, Ph.D., will depart from his position as Chief Executive Officer of the Company and as a member of the Board, effective December 31, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Yvonne L. Greenstreet was appointed as Director at ALNYLAM PHARMACEUTICALS, INC..

Action: appointed
Role: Director

Exact text from the filing

the Board expanded the size of the Board from eleven to twelve members and elected Dr. Greenstreet to fill the newly created vacancy, in each case effective as of October 28, 2021.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

John M. Maraganore departed as Chief Executive Officer at ALNYLAM PHARMACEUTICALS, INC..

Action: departed
Role: Chief Executive Officer

Exact text from the filing

The Company also announced that, as part of this leadership transition, following nearly 19 years of service, John M. Maraganore, Ph.D., will depart from his position as Chief Executive Officer of the Company and as a member of the Board, effective December 31, 2021.

View on SEC.gov

ALNYLAM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-21-310422

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.